P0154 The significance of inflammatory adhesion in stage II colorectal cancer and CXCL10/CXCR3 overexpression as a possible biomarker of poor prognosis

Background: We aimed to assess radiological response and pathological complete response with neoadjuvant chemotherapy regimens in breast cancer at our hospital, which serves a population of 1.5 million. Methods: Patient details were obtained retrospectively between 2011 and 2013 from breast multi-disciplinary meetings, hospital electronic data systems. Data were stratified and analysed. Findings: Twenty-nine of 1310 patients (2.2%) discussed at multidisciplinary meetings had neoadjuvant chemotherapy. All were women, median age 48 years (range 28–72), 15/29 (52%) were oestrogen-receptor positive, 14/29 (48%) were HER2 positive, 13/29 (45%) were triple negative, 13/29 (45%) had grade 2 disease, 15/29 (51%) had grade 3 disease, and 4/29 (13%) had inflammatory breast cancer. Most patients (69%) received FEC -D (fluorouracil, epirubicin, and cyclophosphamide with docetaxel). The rest (31%) received FEC-100 for six to eight cycles. Eighteen of 29 (62%) patients had a radiological response and none had progressive disease. Two cases had no response.The majority of those responding were HER2 and triple negative breast cancer patients. Mean tumour size on imaging pre and post neoadjuvant chemotherapy were 41 and 26 mm respectively. Six (21%) patients had a pathological complete response following neoadjuvant chemotherapy. Interpretation: Rates of pathological complete response in our centre were encouraging and in keeping with those reported nationally and internationally. There were no reports of disease progression of the primary tumour whilst on neoadjuvant chemotherapy within the study period. We recommend neoadjuvant chemotherapy as an option particularly for HER2-positive disease and for those with triplenegative breast cancer in early stage.